A Study of Enasidenib in People With T-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnoza chłoniaka AITL z mutacją IDH2
- •Choroba, która wróciła lub pogorszyła się po wcześniejszym leczeniu
- •Co najmniej 2 tygodnie przerwy od poprzedniego leczenia onkologicznego
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Wyniki badań krwi i funkcji nerek na odpowiednim poziomie
- •Mierzalne oznaki choroby nowotworowej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, United States
Memorial Sloan Kettering Cancer Center (Limited Protocol Activities)
Basking Ridge, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
Commack, United States
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, United States
Memorial Sloan Kettering Nassau (Limited protocol activities)
Uniondale, United States
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.